| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 9, 2019Key data results:
Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore....
-
Dec 5, 2019Latest Initiative of #ThisIsMBC to be Unveiled at the 2019 San Antonio Breast Cancer Symposium
Eisai Inc. and METAvivor today announced the launch of Beneath the Breast, a new initiative of the #ThisIsMBC campaign. Beneath the Breast spotlights imagery of eight people living with metastatic...
-
Dec 2, 2019New Data from Eisai's Robust Dementia Pipeline Will Be Shared, Including Analyses of Investigational Alzheimer's Disease Compounds and Diagnostic Methods
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new data from the company's rich dementia pipeline, including BAN2401, lemborexant and diagnostics methods, will...
-
Nov 25, 2019Key presentations include:
Eisai Inc. today will present FYCOMPA® (perampanel) CIII data on convulsive seizure freedom and additional analyses of FYCOMPA at the upcoming American Epilepsy Society Annual Meeting taking...
-
Nov 12, 2019Ella the Jellyfish Brings Comfort and Support to Children with LGS as well as their Families and Caregivers
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., today announced the launch of Ella the Jellyfish, the first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS). The...
